-DOCSTART- -X- O
The -X- _ O
essentiality -X- _ O
of -X- _ O
zinc -X- _ O
in -X- _ O
humans -X- _ O
was -X- _ O
established -X- _ O
in -X- _ O
1963. -X- _ O
During -X- _ O
the -X- _ O
past -X- _ O
50 -X- _ O
y -X- _ O
, -X- _ O
tremendous -X- _ O
advances -X- _ O
in -X- _ O
both -X- _ O
clinical -X- _ O
and -X- _ O
basic -X- _ O
sciences -X- _ O
of -X- _ O
zinc -X- _ O
metabolism -X- _ O
in -X- _ O
humans -X- _ O
have -X- _ O
been -X- _ O
observed. -X- _ O
The -X- _ O
major -X- _ O
factor -X- _ O
contributing -X- _ O
to -X- _ O
zinc -X- _ B-Intervention
deficiency -X- _ I-Intervention
is -X- _ O
high -X- _ O
phytate-containing -X- _ O
cereal -X- _ O
protein -X- _ O
intake -X- _ O
in -X- _ O
the -X- _ O
developing -X- _ O
world -X- _ O
, -X- _ O
and -X- _ O
nearly -X- _ O
2 -X- _ O
billion -X- _ O
subjects -X- _ O
may -X- _ O
be -X- _ O
zinc -X- _ B-Intervention
deficient. -X- _ I-Intervention
Conditioned -X- _ B-Intervention
deficiency -X- _ I-Intervention
of -X- _ I-Intervention
zinc -X- _ I-Intervention
has -X- _ O
been -X- _ O
observed -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
malabsorption -X- _ O
syndrome -X- _ O
, -X- _ O
liver -X- _ O
disease -X- _ O
, -X- _ O
chronic -X- _ O
renal -X- _ O
disease -X- _ O
, -X- _ O
sickle -X- _ O
cell -X- _ O
disease -X- _ O
, -X- _ O
and -X- _ O
other -X- _ O
chronic -X- _ O
illnesses. -X- _ O
Major -X- _ O
clinical -X- _ O
problems -X- _ O
resulting -X- _ O
from -X- _ O
zinc -X- _ B-Intervention
deficiency -X- _ I-Intervention
in -X- _ I-Intervention
humans -X- _ I-Intervention
include -X- _ O
growth -X- _ B-Outcome
retardation -X- _ I-Outcome
; -X- _ I-Outcome
cell-mediated -X- _ I-Outcome
immune -X- _ I-Outcome
dysfunction -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
cognitive -X- _ I-Outcome
impairment. -X- _ I-Outcome
In -X- _ O
the -X- _ O
Middle -X- _ O
East -X- _ O
, -X- _ O
zinc-deficient -X- _ B-Outcome
dwarfs -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
live -X- _ I-Outcome
beyond -X- _ I-Outcome
the -X- _ I-Outcome
age -X- _ I-Outcome
of -X- _ I-Outcome
25 -X- _ I-Outcome
y -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
they -X- _ I-Outcome
died -X- _ I-Outcome
because -X- _ I-Outcome
of -X- _ I-Outcome
intercurrent -X- _ I-Outcome
infections. -X- _ I-Outcome
In -X- _ O
1963 -X- _ O
, -X- _ O
we -X- _ O
knew -X- _ O
of -X- _ O
only -X- _ O
3 -X- _ O
enzymes -X- _ O
that -X- _ O
required -X- _ O
zinc -X- _ O
for -X- _ O
their -X- _ O
activities -X- _ O
, -X- _ O
but -X- _ O
now -X- _ O
we -X- _ O
know -X- _ O
of -X- _ O
> -X- _ O
300 -X- _ O
enzymes -X- _ O
and -X- _ O
> -X- _ O
1000 -X- _ O
transcription -X- _ O
factors -X- _ O
that -X- _ O
are -X- _ O
known -X- _ O
to -X- _ O
require -X- _ O
zinc -X- _ O
for -X- _ O
their -X- _ O
activities. -X- _ O
Zinc -X- _ O
is -X- _ O
a -X- _ O
second -X- _ O
messenger -X- _ O
of -X- _ O
immune -X- _ O
cells -X- _ O
, -X- _ O
and -X- _ O
intracellular -X- _ O
free -X- _ O
zinc -X- _ O
in -X- _ O
these -X- _ O
cells -X- _ O
participate -X- _ O
in -X- _ O
signaling -X- _ O
events. -X- _ O
Zinc -X- _ O
has -X- _ O
been -X- _ O
very -X- _ O
successfully -X- _ O
used -X- _ O
as -X- _ O
a -X- _ O
therapeutic -X- _ O
modality -X- _ O
for -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
acute -X- _ O
diarrhea -X- _ O
in -X- _ O
children -X- _ O
, -X- _ O
Wilsonâ€™s -X- _ O
disease -X- _ O
, -X- _ O
the -X- _ O
common -X- _ O
cold -X- _ O
and -X- _ O
for -X- _ O
the -X- _ O
prevention -X- _ O
of -X- _ O
blindness -X- _ O
in -X- _ O
patients -X- _ O
with -X- _ O
age- -X- _ O
related -X- _ O
dry -X- _ O
type -X- _ O
of -X- _ O
macular -X- _ O
degeneration -X- _ O
and -X- _ O
is -X- _ O
very -X- _ O
effective -X- _ O
in -X- _ O
decreasing -X- _ O
the -X- _ O
incidence -X- _ O
of -X- _ O
infection -X- _ O
in -X- _ O
the -X- _ O
elderly. -X- _ O
Zinc -X- _ O
not -X- _ O
only -X- _ O
modulates -X- _ O
cell-mediated -X- _ O
immunity -X- _ O
but -X- _ O
is -X- _ O
also -X- _ O
an -X- _ O
antioxidant -X- _ O
and -X- _ O
anti-inflammatory -X- _ O
agent -X- _ O
. -X- _ O

